Nafamostat hydrochloride is a broad-spectrum serine protease inhibitor and a kallikrein inhibitor that inhibits blood coagulation; it is also a potential complement inhibitor. It suppresses autoreactive T-cell activity by reducing granzyme activity and cytotoxic T lymphocyte (CTL)-mediated cytolysis. Nafamostat hydrochloride can inhibit the activation of SARS-CoV-2.